Drug development
HBM contact: Dr Alexander Asam
Company status: private
Sublimity Therapeutics develops the first orally delivered, soluble formulation of Cyclosporin to treat Ulcerative Colitis as topical treatment. The company is in Phase II clinical development as has facilities in Ireland and the USA .